Journal
CLINICAL EPIGENETICS
Volume 13, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13148-021-01210-6
Keywords
DNA methylation; Methylome; Epigenetics; Triple-negative breast cancer; Neoadjuvant chemotherapy
Categories
Funding
- National Health and Medical Research Council (NHMRC) [1106870, 1063559, 1156408, 1177792]
- National Breast Cancer Foundation IIRS Grant [IIRS-18-137]
- National Foundation and Medical Research and Innovation grant (NFMRI)
- Cancer Council NSW [RG-18-09]
- Australian Government through NCI Raijin under the National Computational Merit Allocation Scheme 2019 [wk73]
- National Health and Medical Research Council of Australia [1177792, 1106870, 1156408] Funding Source: NHMRC
Ask authors/readers for more resources
Neoadjuvant chemotherapy for triple-negative breast cancer requires accurate biomarkers to predict patient response. A study found 9 differentially methylated regions associated with NAC response in TNBC, with 4 of these regions also linked to overall survival. This highlights the potential of DNA methylation biomarkers for predicting NAC response in TNBC.
Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient's response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation profiling on diagnostic TNBC biopsy samples from the Sequential Evaluation of Tumours Undergoing Preoperative (SETUP) NAC study. We found 9 significantly differentially methylated regions (DMRs) at diagnosis which were associated with response to NAC. We show that 4 of these DMRs are associated with TNBC overall survival (P < 0.05). Our results highlight the potential of DNA methylation biomarkers for predicting NAC response in TNBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available